Global Small Interfering RNA (siRNA)-based Therapeutics Market Research Report 2025

Publication ID:

PB505257938

Publication Date:

May 30, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Small Interfering RNA (siRNA)-based Therapeutics was valued at US$ 2047 million in the year 2024 and is projected to reach a revised size of US$ 10960 million by 2031, growing at a CAGR of 27.5% during the forecast period.
Small Interfering RNA (siRNA) drugs are a class of nucleic acid-based therapeutics that utilize short RNA molecules to silence or regulate the expression of specific genes. These drugs have the ability to interfere with the translation of messenger RNA (mRNA) into proteins, effectively "silencing" the gene associated with that mRNA. SiRNA-based therapies have the potential to treat a variety of diseases, particularly those with a genetic or RNA-based component.
The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.
This report aims to provide a comprehensive presentation of the global market for Small Interfering RNA (siRNA)-based Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Interfering RNA (siRNA)-based Therapeutics.
The Small Interfering RNA (siRNA)-based Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Small Interfering RNA (siRNA)-based Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Small Interfering RNA (siRNA)-based Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam
Novartis
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Segment by Type
GIVLAARI
Onpattro
OXLUMO
AMVUTTRA
Leqvio
Segment by Application
AHP
hATTR
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Small Interfering RNA (siRNA)-based Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 GIVLAARI
1.2.3 Onpattro
1.2.4 OXLUMO
1.2.5 AMVUTTRA
1.2.6 Leqvio
1.3 Market by Application
1.3.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 AHP
1.3.3 hATTR
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Perspective (2020-2031)
2.2 Global Small Interfering RNA (siRNA)-based Therapeutics Growth Trends by Region
2.2.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Small Interfering RNA (siRNA)-based Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Small Interfering RNA (siRNA)-based Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Small Interfering RNA (siRNA)-based Therapeutics Market Dynamics
2.3.1 Small Interfering RNA (siRNA)-based Therapeutics Industry Trends
2.3.2 Small Interfering RNA (siRNA)-based Therapeutics Market Drivers
2.3.3 Small Interfering RNA (siRNA)-based Therapeutics Market Challenges
2.3.4 Small Interfering RNA (siRNA)-based Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Interfering RNA (siRNA)-based Therapeutics Players by Revenue
3.1.1 Global Top Small Interfering RNA (siRNA)-based Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Small Interfering RNA (siRNA)-based Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Small Interfering RNA (siRNA)-based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Small Interfering RNA (siRNA)-based Therapeutics Revenue
3.4 Global Small Interfering RNA (siRNA)-based Therapeutics Market Concentration Ratio
3.4.1 Global Small Interfering RNA (siRNA)-based Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Interfering RNA (siRNA)-based Therapeutics Revenue in 2024
3.5 Global Key Players of Small Interfering RNA (siRNA)-based Therapeutics Head office and Area Served
3.6 Global Key Players of Small Interfering RNA (siRNA)-based Therapeutics, Product and Application
3.7 Global Key Players of Small Interfering RNA (siRNA)-based Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Interfering RNA (siRNA)-based Therapeutics Breakdown Data by Type
4.1 Global Small Interfering RNA (siRNA)-based Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Small Interfering RNA (siRNA)-based Therapeutics Forecasted Market Size by Type (2026-2031)
5 Small Interfering RNA (siRNA)-based Therapeutics Breakdown Data by Application
5.1 Global Small Interfering RNA (siRNA)-based Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Small Interfering RNA (siRNA)-based Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Small Interfering RNA (siRNA)-based Therapeutics Market Size (2020-2031)
6.2 North America Small Interfering RNA (siRNA)-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2020-2025)
6.4 North America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Size (2020-2031)
7.2 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2020-2025)
7.4 Europe Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Small Interfering RNA (siRNA)-based Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Interfering RNA (siRNA)-based Therapeutics Market Size (2020-2031)
9.2 Latin America Small Interfering RNA (siRNA)-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Small Interfering RNA (siRNA)-based Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam
11.1.1 Alnylam Company Details
11.1.2 Alnylam Business Overview
11.1.3 Alnylam Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.1.4 Alnylam Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.1.5 Alnylam Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.2.4 Novartis Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Sylentis
11.3.1 Sylentis Company Details
11.3.2 Sylentis Business Overview
11.3.3 Sylentis Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.3.4 Sylentis Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.3.5 Sylentis Recent Development
11.4 Arrowhead
11.4.1 Arrowhead Company Details
11.4.2 Arrowhead Business Overview
11.4.3 Arrowhead Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.4.4 Arrowhead Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.4.5 Arrowhead Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Details
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.5.5 Silence Therapeutics Recent Development
11.6 Dicerna
11.6.1 Dicerna Company Details
11.6.2 Dicerna Business Overview
11.6.3 Dicerna Small Interfering RNA (siRNA)-based Therapeutics Introduction
11.6.4 Dicerna Revenue in Small Interfering RNA (siRNA)-based Therapeutics Business (2020-2025)
11.6.5 Dicerna Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Alnylam
Novartis
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂